Raad Micheal, Xu Amy L, Ortiz-Babilonia Carlos, Marrache Majd, Durand Wesley M, Greenberg Marc, Jain Amit
Department of Orthopaedic Surgery, Johns Hopkins University, Baltimore, MD.
Department of Orthopaedic Surgery, University of Puerto Rico Medical Sciences Campus, San Juan, PR.
Spine (Phila Pa 1976). 2023 Mar 1;48(5):330-334. doi: 10.1097/BRS.0000000000004526. Epub 2022 Nov 1.
Retrospective cost-utility analysis.
To conduct a cost-analysis comparing synthetic cage (SC) versus allograft (Allo) over a five-year time horizon.
SC and Allo are two commonly used interbody choices for anterior cervical discectomy and fusion (ACDF) surgery. Previous analyses comparative analyses have reached mixed conclusions regarding their cost-effectiveness, yet recent estimates provide high-quality evidence.
A decision-analysis model comparing the use of Allo versus SC was developed for a hypothetical 60-year-old patient with cervical spondylotic myelopathy undergoing single-level ACDF surgery. A comprehensive literature review was performed to estimate probabilities, costs (2020 USD) and quality-adjusted life years (QALYs) gained over a five-year period. A probabilistic sensitivity analysis using a Monte Carlo simulation of 1000 patients was carried out to calculate incremental cost-effectiveness ratio and net monetary benefits. One-way deterministic sensitivity analysis was performed to estimate the contribution of individual parameters to uncertainty in the model.
The use of Allo was favored in 81.6% of the iterations at a societal willing-to-pay threshold of 50,000 USD/QALY. Allo dominated (higher net QALYs and lower net costs) in 67.8% of the iterations. The incremental net monetary benefits in the Allo group was 2650 USD at a willing-to-pay threshold of 50,000 USD/QALY. One-way deterministic sensitivity analysis revealed that the cost of the index surgery was the only factor which significantly contributed to uncertainty.
Cost-utility analysis suggests that Allo maybe a more cost-effective option compared with SCs in adult patients undergoing ACDF for cervical spondylotic myelopathy.
回顾性成本效用分析。
进行一项成本分析,比较在五年时间范围内使用人工合成椎间融合器(SC)与同种异体移植物(Allo)的情况。
SC和Allo是颈椎前路椎间盘切除融合术(ACDF)中两种常用的椎间融合选择。以往的比较分析对它们的成本效益得出了不同结论,但近期的评估提供了高质量证据。
针对一名假设的60岁患有脊髓型颈椎病并接受单节段ACDF手术的患者,开发了一个比较使用Allo与SC的决策分析模型。进行了全面的文献综述,以估计五年期间的概率、成本(2020年美元)和获得的质量调整生命年(QALY)。使用对1000名患者的蒙特卡洛模拟进行概率敏感性分析,以计算增量成本效益比和净货币效益。进行单向确定性敏感性分析,以估计各个参数对模型不确定性的贡献。
在社会支付意愿阈值为50,000美元/QALY时,81.6%的迭代中倾向于使用Allo。在67.8%的迭代中,Allo占主导地位(更高的净QALY和更低的净成本)。在支付意愿阈值为50,000美元/QALY时,Allo组的增量净货币效益为2650美元。单向确定性敏感性分析表明,初次手术的成本是唯一对不确定性有显著贡献的因素。
成本效用分析表明,在因脊髓型颈椎病接受ACDF的成年患者中,与SC相比,Allo可能是一种更具成本效益的选择。